QI
NVO

QV Investors’s Novo Nordisk NVO Stock Holding History

QV Investors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Buy
369,468
+81,870
+28% +$3.52M 1.36% 25
2026
Q1 		$10.6M Buy
287,598
+79,330
+38% +$3.76M 0.86% 36
2025
Q4 		$10.6M Sell
208,268
-14,890
-7% -$761K 0.87% 37
2025
Q3 		$12.4M Buy
223,158
+97,044
+77% +$5.68M 1.07% 32
2025
Q2 		$8.7M Buy
126,114
+118,420
+1,539% +$8.05M 0.85% 35
2025
Q1 		$534K Sell
7,694
-580
-7% -$47.9K 0.05% 65
2024
Q4 		$712K Sell
8,274
-180
-2% -$19.5K 0.07% 63
2024
Q3 		$1.01M Buy
8,454
+40
+0.5% +$5.33K 0.09% 63
2024
Q2 		$1.2M Buy
8,414
+50
+0.6% +$6.63K 0.11% 61
2024
Q1 		$1.07M Sell
8,364
-14,890
-64% -$1.77M 0.09% 62
2023
Q4 		$2.41M Sell
23,254
-47,030
-67% -$4.65M 0.22% 60
2023
Q3 		$6.39M Sell
70,284
-29,120
-29% -$2.57M 0.66% 46
2023
Q2 		$8.04M Sell
99,404
-4,260
-4% -$348K 0.72% 43
2023
Q1 		$8.25M Sell
103,664
-11,806
-10% -$837K 0.77% 38
2022
Q4 		$7.81M Buy
115,470
+1,380
+1% +$80.9K 0.75% 40
2022
Q3 		$5.68M Sell
114,090
-3,260
-3% -$175K 0.55% 48
2022
Q2 		$6.54M Sell
117,350
-46,240
-28% -$2.57M 0.6% 44
2022
Q1 		$9.08M Sell
163,590
-2,920
-2% -$150K 0.65% 41
2021
Q4 		$9.32M Sell
166,510
-113,480
-41% -$6.15M 0.65% 40
2021
Q3 		$13.4M Sell
279,990
-85,000
-23% -$4.11M 1.02% 34
2021
Q2 		$15.3M Sell
364,990
-11,020
-3% -$427K 0.93% 32
2021
Q1 		$12.7M Sell
376,010
-26,740
-7% -$952K 0.78% 39
2020
Q4 		$14.1M Sell
402,750
-76,500
-16% -$2.64M 0.92% 30
2020
Q3 		$16.6M Sell
479,250
-53,220
-10% -$1.77M 1.13% 32
2020
Q2 		$17.4M Sell
532,470
-136,772
-20% -$4.36M 1.17% 29
2020
Q1 		$20.1M Sell
669,242
-126,758
-16% -$3.77M 1.72% 16
2019
Q4 		$23M Buy
796,000
+114,640
+17% +$3.17M 0.97% 25
2019
Q3 		$17.6M Buy
681,360
+508,720
+295% +$12.9M 0.53% 34
2019
Q2 		$4.41M Buy
+172,640
New +$4.27M 0.14% 56

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

QV Investors's NVO Position: Q2 2026 in Review

QV Investors increased its Novo Nordisk (NVO) stake by 28% in Q2 2026, buying an estimated $3.52M and bringing the position to 369,468 shares worth $17.7M. The position accounts for 1.36% of the portfolio, ranked #25.

QV Investors first reported a position in NVO in Q2 2019 and has held it in 29 quarters since. The position peaked at $23M in Q4 2019. 401 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • QV Investors held 369,468 shares of Novo Nordisk worth $17.7M as of Q2 2026.
  • QV Investors bought 81,870 Novo Nordisk shares in Q2 2026, an estimated $3.52M.
  • Novo Nordisk made up 1.36% of QV Investors's portfolio in Q2 2026, its #25 holding.
  • QV Investors first reported a position in Novo Nordisk in Q2 2019 and has held it in 29 quarters since.
  • QV Investors's Novo Nordisk position peaked at $23M in Q4 2019.
  • 401 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on QV Investors's 13F filing for Q2 2026, filed 21 Jul 2026.